INTRODUCTION
Type 1 diabetes mellitus (T1DM) is caused by autoi mmune mediated destruction of insulin producing βcells in the pancreatic islets [1] . Uncontrolled hyperglycaemia leads to debilitating and in some cases lifelimiting complications including retinopathy, nephropathy, neuropathy and metabolic ketoacidosis [25] . Protection against these ailments by insulin injections requires frequent monitoring of blood glucose to prevent over or underdosage. Hypoglycaemic episodes are not uncommon especially in brittle diabetes where patients often exhibit hypoglycaemia unawareness resulting in dangerous iatrogenic hypoglycaemia [6] . Cellular delivery of insulin achieved by replacement of pancreatic βcells can help manage diabetes and in some cases eliminate the need for exogenous insulin therapy [7] . At present, the two methods employed to replace lost βcells in T1DM are pancreatic transplantation (PTx) and islet transplantation (ITx) [8] . PTx involves an invasive procedure performed in combination with kidney transplantation and necessitates chronic immuno suppression to prevent graft rejection [9, 10] . In contrast, ITx represents a less invasive alternative to PTx where islets are isolated by enzymatic digestion of donor pancreata and then administered to the recipient by percutaneous infusion into the liver via the portal vein [8] . While less risky than whole organ transplantation, ITx is limited by the requirement for immunosuppression to prevent rejection and promote longterm islet graft functionality but the majority of patients still revert to insulin use within five years of treatment [11, 12] . Nevertheless, ITx can provide temporary insulin independence and even partial graft function can prevent dangerous hypoglycaemic events [8, 13, 14] . Unfortunately, pancreatic donors are scarce and current practices often require use of islets from two or more separate donors. This practice is not practical on a large scale and so there is a great impetus to find alternative solutions especially given that implant function also frequently fails with time [8] .
One approach to providing a sustainable supply of insulin releasing tissue for transplantation is to generate insulinproducing cells from stem cells or to engineer celllines which mimic the functional response of normal human pancreatic βcells [1518] . Over the years, many rodent βcell lines have been created by methods such as exposure of primary rodent βcells to radiation or transfection with oncogenic viral vectors such as SV40 [1924] . While such celllines have proven invaluable in basic islet research their xenogeneic properties limit their therapeutic utility. Consequently, more recent endeavours have been focused on the creation of insulinreleasing celllines from human βcells [25, 26] . Unfortunately, this has proven to be extremely difficult as human βcells tend to proliferate poorly and undergo rapid dedifferentiation when cultured in vitro. The majority of attempts to develop stable human βcell lines have yielded cells with limited glucose sensitivity or insufficient insulin content [2732] . Extensive functional studies using the novel human βcell line 1.1B4 created by the electrofusion of freshly isolated human βcells with immortal PANC1 epithelial partner cells have demonstrated that 1.1B4 cells possess intact cellular mechanisms for insulin production and secretion, and that they are responsive to glucose and other modulators of insulin secretion [25] . The cells also appear to possess similar cytoprotective mechanisms to primary βcells [3335] . Like many βcelllines, 1.1B4 cells spontaneously form three dimensional pseudoislets after 5 to 7 d when grown in suspension culture. These pseudoislets are morphologically similar to isolated primary islets and show increased expression of cellcell communication genes together with remarkable potentiation of insulin secretory responses to glucose and other secretagogues in vitro [25, 36] . Moreover, 1.1B4 cells showed significantly enhanced resistance to cytotoxicity when configured as pseudoislets compared to monolayers [37] . Transplantation of cells configured as pseudoislets may represent an attractive model to improve graft survival, function and resistance to hyperglycaemia. In the present study the ability of human insulin secreting 1.1B4 cells, ad ministered as single cell suspensions or pseudoislets, to rescue diabetes and restore blood glucose control was studied using severe combined immunodeficient (SCID) mice rendered diabetic by administration of streptozotocin (STZ). These immunodeficient mice were used to prevent rejection of human 1.1B4 cell implants.
MATERIALS AND METHODS

Cell culture and pseudoislet formation
The generation and characterisation of the human 1.1B4 βcell line has been described previously [25] . The cells were maintained at 37 ℃ with 5% CO2 in RPMI1640 media (Gibco ® Invitrogen, Paisley, United Kingdom) containing 11.1 mol/L glucose and 2.0 mol/L Lglutamine supplemented with 10% (v/v) foetal calf serum (Gibco ® Invitrogen, Paisley, United Kingdom) and antibiotics (100 U/mL penicillin and 0.1 g/L streptomycin) (Gibco ® Invitrogen, Paisley, United Kingdom). Cells were given fresh media every 23 d as necessary and were routinely used from passage 2535. The cell line is available to purchase from SigmaAldrich (Dorset, United Kingdom). To form pseudoislets, 1.1B4 cells were seeded at a density of 1 × 10 5 cells/well into ultralowattachment, sixwell, flatbottomed plates (Corning Inc., NY, United States) with 5mL/well culture medium. Cells typically formed threedimensional pseudoislet clusters, each comprising 50006000 cells, within 57 d of seeding [37] . 
Animal and surgical procedures
Biochemical assays
Lysates of excised cell masses and pancreata were prepared by overnight extraction at 4 ℃ with acid ethanol (ethanol 75% v/v, water 23.5% v/v and concentrated HCl 1.5% v/v). Protein contents were determined by Bradford assay. Insulin was determined by radioimmunoassay as described previously [38] . Glucagon was determined using glucagon chemiluminescent assay (EZGLU30K, Millipore, MA, United States) following manufacturer's instructions. Glucose in plasma samples was determined using an Analox GM9 glucose analyzer (Analox, London, United Kingdom).
Immunohistochemistry
For peroxidase immunostaining, dewaxed and rehydrated sections were blocked in 0.3% (v/v) H2O2 in 50% (v/v) methanol for 30 min to quench endogenous peroxidase activity, before incubation at 95 ℃ in citrate buffer (pH 6.0) for antigen retrieval. After cooling, sections were incubated at 4 ℃ with mouse anti insulin antibody (1:1000, Abcam, United Kingdom) overnight, and then incubated with ImmPRESS HRP anti mouse IgG (peroxidase) reagent (Vector labs, United Kingdom) and developed with 3, 3'Diaminobenzidine substrate (Vector labs, United Kingdom). Lastly, sections were counterstained with haematoxylin at 60 ℃ for 5 min, and slides were cleared with Histoclear Ⅱ and mounted with Histomount mounting medium. Slides were viewed using Olympus IX51 inverted microscope and photographed using the SPOT RTKe camera (Diagnostic Instruments Inc., Sterling Heights, MI, United States).
For fluorescence immunostaining, following dewaxing, rehydration, antigen retrieval with citrate buffer and blocking with BSA solution, sections were incubated at 4 ℃ overnight with primary antibodies (mouse anti insulin antibody, ab6995, 1:1000, Abcam; guinea pig anti glucagon antibody, PCA2/4, raised in house; rabbit anti Ki67 antibody, ab15580, 1:100, Abcam) prior to incubation at 37 ℃ for 45 min with secondary antibody (Alexa Fluor 488/594) [35, 39] . Finally, slides were mounted with antifade mounting medium and viewed under FITC filter (488 nm) or TRITC filter using a fluorescent microscope (Olympus, model BX51) and photographed using a connected DP70 camera adapter system.
Image analysis
Closed polygon tool in CellF image analysis software (Olympus Soft Imaging Solutions, GmbH) was used to analyze islet parameters including islet, a cell and β cell areas. Number of islets was counted in a blinded fashion and expressed as number per mm 2 of pancreas.
For analysis of islet size distribution, islets smaller than 10000 µm 2 were considered small, those larger than 10000 µm 2 but smaller than 25000 µm 2 were considered medium and those larger than 25000 µm 2 were considered large. Cells expressing both insulin and either Ki67 or TUNEL were counted and values were expressed as a percentage of the total number of insulin positive cells observed. Approximately 1000 βcells were analyzed per replicate.
Statistical analysis
Results are expressed as mean ± SEM. Groups of data were compared using Student's unpaired ttest with twotailed P-values. Groups were considered significant where P < 0.05.
RESULTS
Effects on food and fluid intake, body weight and blood glucose
Streptozotocin diabetes caused significant increases in food and fluid intake when compared to nondiabetic controls (P < 0.05, P < 0.01, P < 0.001, Figure 2A and B).
Implantation of 1.1B4 cell suspensions or pseudoislets had small inhibitory effects on daily and cumulative food intake ( Figure 2A ). 1.1B4 pseudoislet transplantation significantly (P < 0.05) decreased fluid intake from day 18 postimplantation compared to the marked polydipsia exhibited by diabetic controls ( Figure 2B ). Fluid intake of cell suspension recipients did not significantly differ from control diabetic mice, indicating less effective amelioration of blood glucose control. Streptozotocin diabetes resulted in significant and progressive body weight loss compared to nondiabetic controls (P < 0.05, P < 0.01, Figure 2C ). Transplantation of 1.1B4 cells resulted in significantly increased body weight compared to diabetic controls 15 d post transplantation (P < 0.05, Figure 2C ), while pseudoislets evoked a more gradual increase with values differing significantly from diabetic controls from 24 d post transplantation (P < 0.05, Figure 2C ).
Streptozotocin diabetes significantly increased blood glucose levels within 3 d compared to nondiabetic controls (P < 0.001, Figure 2D ). The hyperglycaemia was moderated during the period of insulin treatment but rebounded to very high levels thereafter. Blood glucose was significantly decreased at 12 and 15 d after implantation of 1.1B4 cells (P < 0.001, Figure 2D ) or pseudoislets (P < 0.05, Figure 2D ) respectively. From day 12 onwards, a much more moderate fall of blood glucose was observed in the pseudoislet recipient group (P < 0.05, P < 0.01, Figure 2D ). Indeed, whereas mice receiving 1.1B4 cells were culled at 21 d posttransplantation to avoid severe hypoglycaemia, pseudoislet recipients exhibited normoglycaemia when the study was ter minated at 30 d.
Effects on glucose tolerance
Following an 8 h fast and intraperitoneal glucose ad ministration, blood glucose levels of both 1.1B4 cell suspension and pseudoislet recipients were significantly lower than diabetic control animals at all timepoints observed (P < 0.01, Figure 2E ). Furthermore, 1.1B4 cell suspension implants yielded significantly (P < 0.05) lower blood glucose levels than pseudoislet implants or normal control mice (P < 0.05, P < 0.01, Figure 2E ). Pseudoislet recipients exhibited normal glucose tolerance. Figure 3A) . Streptozotocin diabetes significantly decreased plasma insulin compared to nondiabetic mice (P < 0.001). Insulin concentrations were significantly raised in mice receiving 1.1B4 cell suspension and pseudoislet implants (10.8 and 7.9 fold increases respectively, P < 0.05, P < 0.01, Figure 3B ). Streptozotocin diabetes also significantly decreased pancreatic insulin content (P < 0.05, Figure 3C ) which was not altered by transplantation ( Figure 3C ). Plasma and pancreatic glucagon levels of diabetic mice were significantly increased compared to non-diabetic controls (P < 0.05, P < 0.01, Figure 3D and E) and this was partly normalized by cell transplantation (P < 0.05, Figure 3D and E).
Effects on plasma and pancreatic hormone content
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Effects on pancreatic islets
Representative images showing insulin and glucagon staining in islets of nondiabetic, diabetic and cell/ pseudoislet implanted diabetic mice are shown in Figure  4A . Histological analysis of the islets showed that strepto zotocin markedly diminished islet area, β cell area, β to a cell ratio and number of islets while increasing alpha cell area (P < 0.05, P < 0.01, P < 0.001, Figure 4BF ). Islet areas of 1.1B4 cell suspension recipients were marginally decreased compared to diabetic controls (P < 0.05, Figure 4B ). However, acell areas were decreased and both βcell and β to a-cell ratios were significantly increased in 1.1B4 cell suspension and pseudoislet recipients (P < 0.05, Figure 4CE ). Percentage of smaller islets increased in diabetic mice which was not normalised by cell or pseudoislet transplantation ( Figure  4G ).
Representative images showing Ki67/insulin and TUNEL/insulin staining in islets of nondiabetic, diabetic and cell/pseudoislet implanted diabetic mice are shown in Figure 5A . Diabetes induction was associated with significant decreases in βcell Ki67 to TUNEL ratio indicating an increase in the frequency of βapoptosis and a decrease in βcell proliferation (P < 0.05, Figure   5B -D). Implants did not significantly affect βcell Ki67 or TUNEL expression.
DISCUSSION
The therapeutic potential of novel 1.1B4 human insulin releasing βcells configured as cell suspensions or pseudoislets was assessed by implantation into diabetic SCID mice. 1.1B4 cells exhibit marked decreases in secretory function and viability following prolonged exposure to high levels of glucose [33, 37] . As a result, mice with chemicallyinduced diabetes were given insulin therapy for 927 d after STZ to moderate blood glucose levels during the engraftment of implanted 1.1B4 cell suspensions and pseudoislets. As expected, control STZ treated mice characteristically exhibited hyperphagia, polydipsia, weight loss and marked hyperglycaemia which were temporarily moderated during the period of insulin treatment.
Implantation of 1.1B4 cell suspensions or pseu doislets yielded vascularised cell masses (data not included) which restored plasma insulin concentrations and reversed the hyperglycaemic state. We did not have the opportunity to measure human Cpeptide for confirmation but we assume that this insulin was derived from extrapancreatic source because analysis of pancreatic tissue at end of study revealed severe loss of islet beta cells and cellular insulin in both 1.1B4 cell implanted groups similar to untreated diabetic controls. Furthermore, human insulin and Cpeptide were readily detectable in 1.1B4 cells [25] . This was associated with significant beneficial effects on glucose tolerance, body weight and both, food and fluid intakes, but plasma glucagon remained elevated. These results have parallels with previous studies where primary islets were implanted into insulin controlled diabetic animals [4042] . However, recipients of 1.1B4 cell suspensions progressed to low blood glucose levels such that these mice were terminated at 21 d after transplantation. In contrast, the antihyperglycaemic effects of pseudoislet implants manifested more slowly, achieving stable normoglycaemia without hypoglycaemic complications. Furthermore, energy and fluid balance, body weight, blood glucose and glucose tolerance improved gradually in these mice. This difference is most likely due to improved insulin secretory function in 1.1B4 pseudoislets compared to single isolated cells as described previously in vitro [25, 36, 37, 43] . This better regulated insulin release is supported by similar insulin contents of the two types of resected βcell masses. Nevertheless, part of the difference may also reflect the slower cellular proliferation following pseudoislet implantation.
Administration of STZ to SCID mice was associated with significant decreases in islet number, size and βcell number together with significant acell hyperplasia. These observations accompanied by depletion of pancreatic insulin and enhancement of pancreatic glu cagon, mirror previous studies of animal models of diabetes induced by STZ [35, 39, 4449] . Implantation of 1.1B4 cell suspensions did not affect hormone contents but was associated with decreases in acell and islet areas but an increase in βcell area and the βcell to acell ratio. There were no significant changes in βcell proliferation or apoptosis, so alterations of these processes in islet acells merits further study. However, both pancreatic insulin and glucagon were unchanged in transplanted mice. Given the present interest in changes of a cell populations in diabetes [35, 47, 49] , this observation merits further investigation. The effects on pancreatic hormones and islets were similar in pseudoislet recipients but as with the metabolic effects, they were moderate compared with cell suspension recipients.
Both cell suspensions and, to a lesser extent, 1.1B4 pseudoislets developed into cell masses following transplantation. While no obvious signs of metastasis were apparent in either group following postmortem examination, the tumorigenic nature of the cells remains an obstacle to therapeutic use. 1.1B4 cells configured as pseudoislets exhibited significantly decreased proliferation rates and are selflimiting in size in vitro [36] . This might be a consequence of cellcell contacts playing a role in modulation of proliferation and apoptosis rates. However, it seems likely that an additional factor limiting pseudoislet growth in vitro is hypoxia, a common consequence of culturing cell spheroids in static cultures. This view is supported by the ability of MIN6 mouse βcell pseudoislets cultured in bioreactor with continuous 
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stirring to grow continuously for two wk without exhibiting any signs of hypoxia, reduced functionality, or growth arrest [50] . In vivo 1.1B4 cells pseudoislets were able to quickly muster a blood supply which allowed proliferation of the cells. This contrasts with the limited ability of human islets to establish effective vascularisation which is a major hindrance to clinical islet outcomes [51] . A number of groups have investigated potential ways of getting around the issue of tumorigenicity of engineered βcells which need to be generated in large numbers in culture. The most popular approach is the use of tailored viral vectors which allows the inactivation or excision of oncogenes from the celllines genomes to reverse the immortal status of the cells once enough have been generated for use [17, 26, 32] . If such an approach could potentially be tailored to reverse the tumorigenic status of 1.1B4 cells, the therapeutic qualities observed , β to a cell ratio (E), number of islets (F), and islet size distribution (G) were all determined by quantitative histological analysis using cell^F software. Values are mean ± SEM (n = 5).
a P < 0.05, d P < 0.01 and f P < 0.001 vs diabetic control.
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Green AD et al . in this study could be more usefully exploited for the treatment of T1DM. An additional or alternative approach involves the use of implantation devices that are currently under development [7, 52] . These devices, such as TheraCyte™ macroencapsulation system and nanofiberenabled encapsulation devices support cell function by providing good oxygen tension and protection from autoimmune attack, whilst providing against unwanted growth and spread of implanted cells [7, 52, 53] . To conclude, implantation of human 1.1B4 cells configured as pseudoislets rescued diabetes and signi ficantly improved glucose tolerance, providing stable blood glucose control. Although the results provide proof ofconcept for possible therapeutic use of genetically engineered human βcells configured as pseudoislets, further work to circumvent the tumorigenic properties of the cells, by genetic manipulation using viral vectors or implantation devices, will be required before such an approach can be realised in a clinical setting.
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